The patient’s story began four months earlier with persistent watery diarrhea and recurrent abdominal discomfort that failed to respond to standard therapy for gastritis and duodenitis. Initial blood counts at a local hospital revealed a subtle but telling anomaly: an absolute monocyte count of 1.54 × 10⁹ per liter, above the normal threshold, together with a low platelet count of 66 × 10⁹ per liter. By the time he reached the referral center, his hemoglobin had fallen from 147 to 100 grams per liter, his platelets had dropped further to 62 × 10⁹ per liter, and his monocyte count had climbed to 1.93 × 10⁹ per liter. His spleen was enlarged, and his alkaline phosphatase — an enzyme normally kept below 125 units per liter — had skyrocketed to 1,145.3 units per liter, a biochemical red flag for infiltrative disease in bone and liver.

Imaging deepened the mystery. Contrast-enhanced computed tomography showed a spleen roughly 13 centimeters long studded with mildly enlarged retroperitoneal lymph nodes. Positron emission tomography using fluorodeoxyglucose revealed a gastric wall burning with metabolic activity at a maximum standardized uptake value of 19.1 — a figure more typical of aggressive lymphoma than of chronic indigestion — along with diffusely increased uptake in the spleen and mild hypermetabolism in mediastinal and abdominal nodes. Yet endoscopic biopsies of the stomach and duodenum showed only chronic active gastritis and ulcers, with no infiltrative lesions. The mismatch between spectacular metabolic signals and bland biopsy results pointed the team toward the bone marrow.

What they found there was extraordinary. The marrow biopsy showed dense, multifocal infiltrates of atypical mast cells consuming roughly half of the marrow cellularity, accompanied by grade MF-2 to MF-3 reticulin fibrosis. The aspirate smears told a more nuanced story: atypical mast cells made up 18.5 percent of nucleated cells, just under the 20 percent threshold that the current WHO classification requires for a diagnosis of mast cell leukemia. Because an adequate aspirate was available, the biopsy burden alone could not override that criterion, so the team classified the disease as advanced systemic mastocytosis rather than the leukemic variant. The mast cells displayed the classic aberrant phenotype — bright CD117 with inappropriate CD25 expression — and were positive for tryptase on immunohistochemistry.

Next-generation sequencing locked in the molecular diagnosis. The panel detected the KIT D816V mutation, the pathogenic engine of more than 90 percent of adult systemic mastocytosis cases, at a variant allele frequency of 12.1 percent. But the sequencing revealed far more than a mast-cell clone. A frameshift mutation in TET2 at 64.9 percent variant allele frequency marked a founding epigenetic clone, compounded by a deletion of TET2 exons 3 through 11 — evidence of biallelic inactivation. A SRSF2 p.Pro95Arg splice-factor mutation at 44.6 percent and two independent RUNX1 mutations completed a mutational triad that is a hallmark of CMML. A CEBPA nonsense mutation rounded out the profile. Together with sustained absolute monocytosis lasting more than three months and a flow-cytometric finding that 98 percent of the patient’s monocytes were of the classical CD14-positive, CD16-negative subset, the molecular data satisfied WHO and International Consensus Classification criteria for CMML-1 of the proliferative subtype.

Then came the third clone. Serum free light-chain testing showed lambda light chains elevated to 2,274.69 milligrams per liter against a kappa of just 28.98, crushing the kappa/lambda ratio to 0.0127 — roughly fiftyfold below the lower limit of normal. Immunofixation of serum and urine confirmed a monoclonal lambda component. Flow cytometry identified a lambda-restricted plasma-cell population, and fluorescence in situ hybridization on enriched CD138-positive cells revealed the t(11;14)(q13;q32) translocation fusing the immunoglobulin heavy-chain locus to CCND1, the cyclin D1 gene. Bone marrow biopsy showed at least 20 percent CD138-positive plasma-cell infiltration. Yet the team stopped short of calling it multiple myeloma: no myeloma-defining event was documented, since plasma cells remained below 60 percent, the involved/uninvolved light-chain ratio was about 78.5 rather than above 100, and PET-CT showed no focal bone lesions. They classified it conservatively as a t(11;14)-positive plasma-cell neoplasm under surveillance.

The biology behind this triple concurrency is what makes the case scientifically rich. Systemic mastocytosis with an associated hematologic neoplasm is itself not rare — roughly 30 to 40 percent of systemic mastocytosis patients harbor a second blood cancer, and CMML accounts for about a quarter to a third of those associations. The prevailing model holds that KIT D816V, TET2, and RUNX1 mutations arise in an early hematopoietic progenitor with multilineage potential, which then branches into mast-cell-dominant and monocyte-dominant subclones. This patient’s mutation profile — KIT D816V alongside TET2, SRSF2, and RUNX1 — fits that shared-ancestor model precisely. The plasma-cell disorder, however, is almost certainly an independent B-lineage event. Only isolated case reports have ever linked systemic mastocytosis with plasma-cell dyscrasias, and none have documented all three diseases simultaneously. Mechanistically, mast cells can secrete interleukin-6 and stem cell factor, cytokines known to support myeloma cell survival, and can engage CD40-CD154 signaling that promotes lymphoplasmacytic proliferation — possible, if speculative, links between the clones.

Treatment was tailored to the two clinically active components. The team initiated avapritinib, a potent and selective inhibitor of KIT D816V that overcomes the imatinib resistance conferred by that mutation, combined with azacitidine, a hypomethylating agent directed at the CMML clone and its TET2/SRSF2/RUNX1 signature. Venetoclax, which has shown activity in t(11;14)-positive myeloma, was deliberately withheld because the plasma-cell neoplasm had no documented myeloma-defining event and was not the immediate threat. After three cycles, the results were encouraging: the frequency of watery diarrhea decreased substantially, hemoglobin and platelet counts improved, the absolute monocyte count declined, and the alkaline phosphatase began trending downward. The authors note that overlapping myelosuppression from both drugs — azacitidine’s anemia, neutropenia, and thrombocytopenia, and avapritinib’s thrombocytopenia, bleeding risk, and cognitive effects — demanded careful monitoring. Serial light-chain measurements were unavailable during follow-up, so the plasma-cell clone’s response could not be formally assessed.

Beyond its rarity, the case is a pointed argument for diagnostic integration. No single abnormality in this patient could explain the full picture: the mast-cell disease accounted for the diarrhea and the alkaline phosphatase but not the monocytosis; the CMML explained the monocytes and cytopenias but not the lambda light chains; the plasma-cell clone explained neither the mast-cell burden nor the gastric hypermetabolism. Only by weaving together morphology, multiparameter flow cytometry, immunohistochemistry, FISH cytogenetics, and targeted sequencing could the team assemble three coherent diagnoses from one confusing clinical presentation. For clinicians, the lesson is that when a patient’s findings exceed what one hematologic disease can produce, the marrow — examined with every modern tool — may be hiding more than one answer.

Subject of Research: Coexistence of systemic mastocytosis, chronic myelomonocytic leukemia, and a t(11;14)-positive plasma-cell neoplasm in one patient

Article Title: Case Report: Coexistence of advanced systemic mastocytosis, chronic myelomonocytic Leukemia, and t(11;14)-positive plasma-cell neoplasm: a rare triple-clonal hematologic case

Article References: Yin, J., Luo, J., Huang, L., Wang, L., Zhong, M., Li, M., & Huang, S. (2026). Case Report: Coexistence of advanced systemic mastocytosis, chronic myelomonocytic Leukemia, and t(11;14)-positive plasma-cell neoplasm: a rare triple-clonal hematologic case. Frontiers in Oncology, 16, Article 1982665. https://doi.org/10.3389/fonc.2026.1982665

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1982665

Keywords: systemic mastocytosis, chronic myelomonocytic leukemia, plasma-cell neoplasm, KIT D816V, TET2, SRSF2, RUNX1, t(11;14), avapritinib, azacitidine, bone marrow diagnostics, SM-AHN

The study, published in Supportive Care in Cancer, was led by Natalie Tuckey of the South Australian Health and Medical Research Institute and Adelaide University, working in partnership with the advocacy organisation Myeloma Australia. Rather than designing a bespoke intervention from scratch, the team chose to evaluate an existing program called the Be Well Plan, a group-based mental health and wellbeing course typically delivered live over five weekly sessions. The program draws on techniques from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness practices and positive psychology, all distilled from a systematic review of what genuinely improves mental wellbeing. Participants learn about thirty evidence-based activities and then build a personalised wellbeing plan, supported by a tracking tool that gives them feedback on their own resilience, strengths and distress.

Crucially, the researchers deferred any myeloma-specific adaptation until after the feasibility testing, a decision grounded in implementation science. The Be Well Plan had already been tested successfully in university students and, in a previous pilot by the same group, in women with breast cancer, where it showed clear mental health benefits. Before launching the myeloma pilot, the team consulted consumer advocates, specialist nurses, experts in culturally and linguistically diverse populations and mental health program designers, who agreed the intervention was likely suitable as delivered. The logic was that real-world feedback from actual patients would reveal refinements that a priori co-design could not anticipate, increasing the likelihood that a future adapted program would be accepted, implemented and sustained in clinical practice.

Twenty consumers aged between 38 and 72 took part, sixteen with multiple myeloma and four with smouldering myeloma, alongside four Myeloma Australia nurses who joined the sessions to inform future delivery. Recruitment ran for four weeks, drawing thirty-seven expressions of interest, of whom twenty-four completed baseline questionnaires. Twenty attended at least one session, averaging 4.2 of the five planned sessions, and all five sessions were delivered as planned via Zoom by a clinical psychologist and certified facilitator. The nurses were placed in separate breakout rooms during peer discussions so that patients could speak freely. Notably, more than half of those who withdrew before starting were from rural or regional areas, a signal the authors flag as a critical accessibility issue for future rollouts.

The quantitative results, while preliminary, were striking. Using a repeated measures multivariate analysis of variance across seventeen participants who completed both pre- and post-intervention measures, the team found a significant multivariate effect of time, with follow-up univariate tests revealing large improvements in mental wellbeing, measured on the Warwick-Edinburgh Mental Wellbeing Scale, and in empowerment, assessed with a modified health empowerment scale. Wellbeing scores rose from an average of 49.42 to 53.21, and empowerment scores climbed from 22.58 to 24.95, with partial eta squared values of 0.24 and 0.25 respectively, both well above the conventional threshold of 0.14 for a large effect. Changes in anxiety and depression, measured with the GAD-7 and PHQ-9, did not reach statistical significance, but their effect sizes fell in the medium to large range, suggesting that a properly powered trial may yet detect meaningful reductions in clinical symptoms.

One finding illustrates the messy reality of psychosocial research in cancer populations. The results proved sensitive to a single participant who experienced a substantial health decline during the intervention period, dragging down the group’s mental health outcomes. When exploratory analyses were repeated with that individual removed, all four outcomes showed significant, large effect size improvements. Yet the same participant continued attending the program and reported finding value in it, a paradox the authors say highlights why future trials must plan for the physical health fluctuations that are inevitable in this population. In a disease where bone pain, fatigue and chemotherapy-related cognitive fog can strike without warning, even the most carefully designed psychological study must accommodate the body’s unpredictability.

The qualitative arm of the study, analysed through inductive thematic analysis of focus groups, interviews and survey free-text responses, yielded three central themes. The first was the power of peer connection: patients described moving from distress and anger toward acceptance and gratitude, and valued meeting others living with the same condition, even when they were at very different disease stages. One participant noted that someone might suggest an approach you had never considered, helping your days get better. The second theme was the need for myeloma-specific content, with patients calling for clearer disease psychoeducation, simplified materials and better pacing, with one respondent pointing out that chemotherapy fog affecting concentration is a real thing and that bone pain or severe fatigue can make attending sessions extremely difficult.

The third theme concerned implementation: how the program should be delivered, by whom, and how it could be woven into routine myeloma care rather than offered as a separate service. Patients and nurses alike emphasised promotion by specialist nurses, collaboration with rehabilitation services and alignment with organisations such as Myeloma Australia. They also acknowledged risks, including potential distress for participants and emotional burden for facilitators, underscoring the need for structured facilitator support and clear strategies for managing group dynamics and sensitive content. Interestingly, the authors caution that the program must not drift into becoming purely a peer support group, since some participants preferred to focus on mental health strategies rather than hear detailed personal stories, which occasionally caused them distress.

Satisfaction with the program was encouraging, with 79 percent of respondents reporting they were satisfied or very satisfied, and nearly three-quarters saying the content presented new information most of the time. However, 36.9 percent indicated the program was not relevant to them some or most of the time, a figure that directly motivates the planned myeloma-specific adaptation. The study’s limitations are candidly acknowledged: the one-arm pre-post design without randomisation or a control group precludes causal inference, the sample was small and entirely self-selected among Caucasian and European consumers who expressed interest in research, and there was no long-term follow-up to determine whether gains persisted. The authors are explicit that these findings establish feasibility and identify necessary adaptations, not clinical effectiveness.

What makes the study notable is its methodological honesty and its commitment to consumer-informed research, an approach that remains inconsistently executed across health research despite widespread endorsement. By involving patients from the initial forums that identified the gap in myeloma mental health support through to the final review of themes, and by including both multiple myeloma and smouldering myeloma patients in recognition of their shared psychosocial challenges across the disease continuum, the team has built a foundation for a program designed to resonate with its intended audience. The next step is a co-designed, myeloma-tailored version of the Be Well Plan, tested in a larger randomised controlled trial with longer follow-up. For a patient population facing an incurable disease, the message from this pilot is quietly hopeful: psychological support built with patients, not just for them, can move the needle on wellbeing and empowerment, and the roadmap for proving it at scale now exists.

Subject of Research: Feasibility of a consumer-informed mental health program for people with multiple myeloma and smouldering myeloma

Article Title: Adapting a mental health program for people with multiple myeloma and smouldering myeloma: a consumer-informed feasibility study

Article References: Tuckey, N., Iasiello, M., Cantley, M., van Agteren, J., Beer, H., Fassnacht, D. B., Ramsey, I., Edney, L. C., Moussa, R. S., Grundy, L., Ryan, M., Ali, K., & Wardill, H. R. (2026). Adapting a mental health program for people with multiple myeloma and smouldering myeloma: a consumer-informed feasibility study. Supportive Care in Cancer, 34(10), Article 937. https://doi.org/10.1007/s00520-026-11163-2

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11163-2

Keywords: multiple myeloma, smouldering myeloma, mental health, wellbeing, consumer-informed research, psycho-oncology, Be Well Plan, feasibility study, empowerment, anxiety, depression, implementation science

Acute myeloid leukaemia, or AML, disrupts the production of healthy blood cells and progresses rapidly, making early and effective treatment critical. Around one-third of patients carry a mutation in a gene called NPM1, one of the most frequently altered genes in this disease. The NPM1 gene provides instructions for a protein that normally resides in the nucleus, the compartment housing the cell’s genetic material. In patients with the mutation, the protein accumulates in the cytoplasm, the surrounding fluid of the cell, and this mislocalisation plays a central role in driving the cancer. Understanding precisely why the protein ends up in the wrong place has therefore been a major goal of leukaemia research.

Until now, most explanations have focused on transport: how the mutated protein shuttles between the nucleus and the cytoplasm. The new study, led by Dr Daniel Booth and Dr Claire Seedhouse at the University of Nottingham’s School of Medicine, shows that this picture is incomplete. Something important happens during cell division itself, when the cell dismantles its nucleus and its chromosomes are exposed in the cytoplasm. The research reveals a previously unknown mechanism that helps explain how the mutation disrupts the normal organisation of proteins inside leukaemia cells.

At the heart of the discovery is the mitotic chromosome periphery, a protective layer that surrounds chromosomes during cell division and has received relatively little scientific attention. Using advanced microscopy, genetic engineering and protein-mapping techniques, the researchers found that healthy NPM1 attaches to this layer during mitosis. This attachment acts like a bookmark: when division is complete and the nucleus re-forms, the protein uses the chromosome surface as a reference point to find its way back to its correct location. In leukaemia cells, this process fails. Dr Booth described the chromosome surface as a temporary docking station that helps proteins return to the right place after a cell divides, and noted that in leukaemia cells this docking does not work properly.

The mutated NPM1 protein behaves in two distinct abnormal ways. It fails to attach properly to the chromosome periphery, instead forming abnormal clusters or dispersing throughout the cell. Worse still, the mutant protein actively interferes with the healthy NPM1 protein produced by the normal copy of the gene, further disrupting its ability to return to the right place after division. Together, these findings reveal two previously unrecognised ways in which cell division contributes to the abnormal positioning of NPM1 in leukaemia, adding a new dimension to a problem that researchers had largely framed as one of transport between cellular compartments.

Perhaps the most exciting aspect of the study is that the researchers showed the process could be partially restored in laboratory experiments. By increasing levels of Ki-67, a protein that helps organise the chromosome periphery, the team created a thicker protective layer around the chromosomes. This improved the attachment of mutant NPM1 to the chromosomes in laboratory-grown leukaemia cells, helping to restore its correct positioning and the normal organisation of the cell. The result suggests that manipulating the chromosome periphery could, in principle, correct one of the fundamental defects that sustains the disease.

The involvement of Ki-67 adds a surprising twist. The protein is widely used in clinics as a marker of cell proliferation and is generally associated with more aggressive cancers, so one might expect higher Ki-67 levels to signal a worse prognosis. However, when the team analysed publicly available patient data, a more complex picture emerged: among patients with this particular form of AML, higher Ki-67 levels showed an unexpected trend towards better survival. The researchers stress that this observation requires further investigation, but it hints that the protein’s role in organising the chromosome periphery may be more protective than its reputation suggests.

Critically, the team confirmed that the newly identified mechanism occurs in samples taken directly from AML patients, not only in laboratory-grown cells. This strengthens the clinical relevance of the findings and suggests that the defective docking of NPM1 at the chromosome periphery is a genuine feature of the disease in patients rather than an artefact of cell culture. Dr Seedhouse said that what is particularly exciting is that the team has shown the process can be improved experimentally, adding that although the work is at an early stage, it reveals a completely new way of thinking about how this form of leukaemia develops and, potentially, how it might be treated.

The discovery challenges the longstanding view that abnormal movement of NPM1 between the nucleus and the cytoplasm is the principal explanation for its mislocalisation. Instead, it identifies interactions between proteins and chromosomes during cell division as another important contributor to the disease. If the findings can be translated into therapies, they would represent a fundamentally new strategy: rather than blocking the mutant protein’s transport, future treatments might aim to strengthen the chromosome periphery so that proteins can find their way home after each cell division. Such an approach could potentially complement existing therapies for AML, a disease in which new treatment options remain urgently needed.

The implications may also extend well beyond leukaemia. The abnormal positioning of proteins inside cells is involved in a range of diseases, and understanding how cells organise their proteins during division could open new avenues of research into other conditions. By uncovering an unexpected link between chromosome biology and blood cancer, the Nottingham team has revealed a new direction for understanding, and potentially treating, diseases driven by misplaced proteins, and has highlighted the mitotic chromosome periphery, long a neglected corner of cell biology, as a promising target for future medicine.

Subject of Research: How the NPM1 mutation disrupts protein positioning at the mitotic chromosome periphery in acute myeloid leukaemia

Article Title: Scientists uncover overlooked mechanism driving aggressive leukemia

Article References: Scientists uncover overlooked mechanism driving aggressive leukemia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: acute myeloid leukaemia, NPM1, cell division, chromosome periphery, Ki-67, protein mislocalisation, University of Nottingham, blood cancer, mitosis, leukaemia research, Nature, mutation

The scale of the disparity is difficult to overstate. Adolescents and young adults, defined in this context as patients between the ages of 15 and 39, and older adults aged 60 and above remain markedly underrepresented in clinical trials despite decades of evidence that trial participation correlates with access to cutting-edge therapies and improved outcomes. The gap is even wider for patients from racially and ethnically minoritized communities, those from lower-income backgrounds, and those treated in community-based settings rather than large academic centers. For a disease category that includes more than 100 distinct blood cancer types, the consequences of this exclusion ripple across the entire research enterprise, limiting the generalizability of trial results and delaying the delivery of new treatments to the very populations that stand to benefit most.

The structural reasons behind these gaps are well documented but notoriously difficult to fix. Eligible patients are often identified late in the course of their care, after treatment decisions have already been made and enrollment windows have closed. Referral pathways between community oncology practices and academic research centers are frequently fragmented, forcing patients and providers to navigate a maze of administrative hurdles at precisely the moment when time is most scarce. Awareness of available trials remains low among both patients and frontline clinicians, and access to dedicated patient navigation services is uneven at best. These barriers compound one another, creating a system in which the patients most likely to benefit from novel therapies are the least likely to encounter them.

Blood cancers add a unique layer of urgency to this problem. Unlike many solid tumors, where patients may have weeks or months to weigh treatment options, blood malignancies such as acute leukemias often demand immediate therapeutic intervention. The clinical tempo leaves little room for the deliberate consideration of clinical trial opportunities, and patients who might otherwise enroll find themselves swept into standard treatment pathways before research options can even be discussed. Any intervention designed to improve trial access in this space must therefore operate faster than the disease itself, identifying eligible patients and surfacing trial options at the very beginning of the care journey rather than after treatment plans have crystallized.

The Columbia-led study will evaluate a coordinated, patient-centered intervention that combines three complementary components. The first is AI-assisted patient identification, using computational tools to scan clinical data and flag patients who meet eligibility criteria for active trials, a task that traditionally consumes enormous amounts of clinician time and is prone to human oversight. The second is streamlined provider support, designed to reduce the administrative burden on oncologists and nurses who wish to refer patients to research programs but lack the time or infrastructure to do so efficiently. The third is personalized patient navigation, pairing patients with trained navigators who can guide them through the logistical, financial, and informational barriers that often stand between eligibility and enrollment.

Together, these components are designed to help patients and healthcare teams identify clinical trial opportunities earlier in the treatment trajectory and to connect eligible individuals with research programs at both academic and community cancer centers. The intervention will be evaluated through Blood Cancer United’s Clinical Trial Support Center, a centralized public resource that will serve as the operational backbone of the study. By embedding the research within an existing national infrastructure, the investigators hope to generate findings that are immediately scalable rather than confined to a single institution or health system.

Eric Cooks, Ph.D., Senior Director of Equity in Access Programs at Blood Cancer United, framed the investment as a necessary step toward systemic change. According to Cooks, advancing equity in cancer care requires evidence-based solutions that can be implemented across healthcare settings to address disparities, and the Columbia study will test innovative approaches to connect more patients with potentially life-saving clinical trials while ensuring that advances in blood cancer research reach all communities, including those historically underrepresented in clinical research. The emphasis on cross-setting implementation reflects a growing recognition in the health services research community that interventions confined to elite academic centers, however effective, cannot close population-level gaps on their own.

The study’s focus on health services research, rather than basic or translational science, is itself significant. Health services research examines how care is organized, delivered, and accessed, asking not whether a treatment works but whether the systems surrounding it allow patients to benefit from it in the first place. In oncology, this lens has become increasingly central as the pace of therapeutic innovation outstrips the capacity of existing care infrastructures to deliver it equitably. A breakthrough therapy that never reaches the patients who need it most is, from a public health perspective, only half a breakthrough, and the Equity in Access Research Program was designed specifically to fund the kind of systems-level evidence needed to close that second half of the gap.

Since its launch in 2021, the program has awarded nearly $21 million in funding to support 16 high-impact health services research studies, making it one of the most substantial philanthropic investments in cancer care delivery science. Blood Cancer United has acknowledged support from AstraZeneca and Syndax for the program and related initiatives focused on reducing healthcare disparities in blood cancer care and treatment. The organization, which has evolved continuously since its founding in 1949 to serve people affected by all blood cancer types, funds research, offers free resources and personalized support, and advocates at state and national levels for more accessible and affordable healthcare.

The implications of the Columbia study extend well beyond blood cancer. If the combined model of AI-assisted identification, provider support, and patient navigation proves effective, the findings could inform policy and practice across the broader oncology landscape, offering a template for how health systems, professional societies, and policymakers approach trial access for other underserved populations. The ultimate goal, as the investigators and funders describe it, is to increase access to clinical trials, improve overall participation, and ensure that every patient, regardless of age, geography, income, or background, has the chance to benefit from the remarkable pace of cancer research advances. In a field where the next breakthrough is always in development, the question of who gets to receive it may prove as consequential as the science itself.

Subject of Research: Health services research on equitable clinical trial access for blood cancer patients

Article Title: Blood Cancer United invests $2.5 million in health services research to improve clinical trial participation

Article References: Blood Cancer United invests $2.5 million in health services research to improve clinical trial participation. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Blood Cancer United, clinical trials, health equity, blood cancer, patient navigation, Columbia University, adolescents and young adults, older adults, health services research, Equity in Access Research Program, cancer disparities, AI-assisted screening

The research team followed 156 adults who developed invasive pneumococcal disease and required hospital care in Region Västra Götaland, Sweden, between 2018 and 2023. The median age of the patients was 70 years, a demographic in which both pneumococcal disease and blood malignancies become progressively more common. To determine whether the severe infection was merely bad luck or a signal of hidden vulnerability, the researchers performed detailed immunological workups. They measured antibody levels to detect deficiencies in humoral immunity, and they tested for the presence of M protein, a monoclonal immunoglobulin that serves as a well-established risk marker for blood cancer. A control group of 64 individuals, matched for age and sex but without invasive pneumococcal disease, provided a baseline for comparison.

The results were striking. Among the patients with invasive pneumococcal disease, one in four had M protein detectable in their blood. Monoclonal gammopathy of this kind can occur in established blood cancers, but it is also found in precursor states, conditions that do not yet meet the criteria for malignancy but can, in some patients, progress toward cancer over time. The examinations prompted by the study led to seven patients receiving a diagnosis of blood cancer, while another twelve were diagnosed with a precursor condition that may, in some cases, evolve into malignancy. In a group of just over 150 patients admitted for a severe bacterial infection, that represents a meaningful yield of previously silent disease.

The immune assessments also uncovered antibody deficiencies. Eight patients in the pneumococcal disease group were found to have immunodeficiency, and in seven of them, clinicians were able to start preventive treatment aimed at protecting against future severe infections. Such treatments can include replacement immunoglobulin therapy and tailored vaccination strategies, interventions that can substantially reduce the risk of recurrent invasive disease. By contrast, these abnormalities were considerably less common in the matched control group, reinforcing the idea that invasive pneumococcal infection is not randomly distributed but clusters in people whose immune surveillance is compromised.

The biological logic behind these findings is straightforward once the mechanics of pneumococcal immunity are considered. Streptococcus pneumoniae is an encapsulated bacterium, and its polysaccharide capsule is the principal target of protective antibodies. Clearance of the organism depends heavily on opsonization, the process by which antibodies coat the bacterium and mark it for destruction by phagocytic cells. People with low antibody levels, whether from a primary immunodeficiency or from the antibody-producing B-cell disorders that underlie many blood cancers, are therefore structurally less able to contain the bacterium when it colonizes the respiratory tract. What would be a mild or localized infection in an immunocompetent adult can become a systemic, hospital-requiring illness in someone whose humoral immunity is impaired.

M protein, the marker at the center of the study, is a monoclonal immunoglobulin produced by a single expanded clone of plasma cells or B cells. Its presence in the blood is the hallmark of a spectrum of disorders ranging from the benign-appearing monoclonal gammopathy of undetermined significance to smoldering and symptomatic myeloma. Because monoclonal gammopathies are common in older populations and often remain asymptomatic for years, most are discovered incidentally or not at all. The Gothenburg study suggests that severe pneumococcal disease may function as a clinical flag: when an older adult presents with invasive infection, the probability of finding an underlying monoclonal disorder is high enough that targeted testing could be worthwhile.

Currently, according to the researchers, these tests are not routinely performed after a severe pneumococcal infection. Tor Härnqvist, a doctoral student at the University of Gothenburg and an infectious disease physician at NU Hospital Group, and one of the lead authors of the study, points to the consequence of that gap. “Currently, these tests are not routinely performed after a severe pneumococcal infection. As a result, we may miss patients with undiagnosed blood cancer or immunodeficiency and therefore missing the opportunity to initiate treatment,” he says. The missed opportunity cuts in two directions: blood cancers such as myeloma are generally more treatable when identified before organ damage accumulates, and immunodeficiencies can be mitigated with preventive measures before the next invasive infection occurs.

The study carries implications for vaccination policy as well. Karin Bergman, a doctoral student in the same research group and an infectious disease physician at Södra Älvsborg Hospital, examined how the pneumococcal bacteria causing severe disease have shifted since the pneumococcal conjugate vaccine was introduced into the Swedish childhood vaccination program. Her analysis, part of a doctoral thesis she will soon defend at the University of Gothenburg, shows that the bacterial serotypes covered by the childhood vaccine have decreased sharply in circulation, but they have largely been replaced by other serotypes against which the childhood vaccine offers no protection. This serotype replacement is a well-documented ecological consequence of conjugate vaccination: eliminating vaccine-targeted strains from nasopharyngeal carriage opens ecological space for non-vaccine strains to colonize and spread.

Crucially, the serotypes now driving invasive disease in adults disproportionately affect older adults and individuals with underlying conditions, particularly cancer and compromised immune systems. This creates an uncomfortable alignment: the very populations most vulnerable to severe pneumococcal infection are those most likely to harbor undiagnosed blood cancer or antibody deficiency, and the circulating bacterial strains are precisely those that exploit gaps in adult immunity. “The results show that recommendations on pneumococcal vaccines for adults need to take into account which vaccines are used in children and which bacterial serotypes subsequently circulate in the community,” says Bergman. In other words, adult immunization strategy cannot be designed in isolation from the pediatric program, because the two are epidemiologically linked through the shifting serotype landscape.

Taken together, the findings support a concrete change in clinical practice. The researchers argue that screening for M proteins and antibody levels should be considered in adults who experience invasive pneumococcal disease, since the infection can reveal previously undiagnosed blood cancer and immunodeficiency. Such screening would involve relatively simple blood tests: quantitative measurement of serum immunoglobulins to identify antibody deficiencies, and protein electrophoresis or equivalent methods to detect monoclonal immunoglobulins. For a patient population that is already hospitalized and undergoing extensive workup, the incremental burden would be modest, while the potential benefit, catching a blood cancer or an immune deficiency that would otherwise remain hidden until it caused further harm, could be substantial. As populations age and serotype replacement continues to reshape pneumococcal epidemiology, the severe pneumonia that lands an older adult in the hospital may increasingly deserve to be read not only as an infection, but as a message from the immune system itself.

Subject of Research: Invasive pneumococcal disease as a marker of undiagnosed blood cancer and immunodeficiency in adults

Article Title: Pneumonia can reveal undiagnosed blood cancer

Article References: Pneumonia can reveal undiagnosed blood cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pneumococcal disease, pneumonia, blood cancer, M protein, immunodeficiency, monoclonal gammopathy, Streptococcus pneumoniae, antibody deficiency, pneumococcal vaccine, serotype replacement, University of Gothenburg, Scientific Reports

The research team, working in collaboration with investigators from MD Anderson Cancer Center, Yale University, and Columbia University, tracked more than 12,000 prescriptions for oral blood cancer drugs in 2022 among patients insured through Medicare or commercial health plans. Rather than simply measuring whether patients eventually obtained their medications, the investigators followed each prescription along a complete pathway: from the initial submission at the pharmacy, through the insurer’s approval or rejection decision, to whether the patient ultimately filled the prescription within 90 days. This longitudinal design allowed the researchers to quantify not just a single barrier but a cascade of them, revealing two distinct points at which patients fall away from treatment.

The first drop-off occurs at the pharmacy counter before treatment even begins. At the initial submission, 64.9 percent of prescriptions for Medicare patients and a striking 84 percent of prescriptions for commercially insured patients were rejected by insurers. The most common reasons were prior authorization requirements, in which a prescriber must submit additional documentation to justify the drug, and outright non-coverage, in which the medication simply was not included in the patient’s plan formulary. Among Medicare beneficiaries, 32.1 percent of prescriptions were initially rejected because prior authorization was required, while among commercially insured patients, 27.8 percent were rejected for prior authorization and 17.1 percent because the drug was not covered at all.

Time and persistence resolved many of these rejections. Within 90 days, the share of prescriptions still rejected had fallen dramatically: insurer approval rates climbed to 85 percent for Medicare patients and 62.9 percent for commercially insured patients. Prior authorization rejections in particular proved largely surmountable, falling from 32.1 percent to just 4.6 percent among Medicare patients, and from 27.8 percent to 6.9 percent among commercially insured patients. Non-coverage rejections also declined, dropping to 8.0 percent in the commercial group. The researchers caution that they could not determine whether any individual rejection was clinically appropriate, but the pattern is telling: when insurers that initially refused a drug ultimately approve the very same therapy, the initial refusal appears to have imposed administrative work and treatment delay without changing the clinical outcome.

For patients with aggressive blood cancers, such delays are not trivial. Targeted oral therapies for chronic myeloid leukemia, for example, work best when started promptly, and clinicians generally regard rapid treatment initiation as essential for diseases that can progress over weeks or months. Every day spent navigating paperwork is a day the underlying malignancy continues to advance. The study’s authors argue that the sheer volume of initial rejections, most of which are later reversed, suggests that prior authorization may function less as a clinical safeguard and more as a friction-generating gatekeeper, one whose costs are borne by patients, oncology practices, and pharmacy staff alike.

The second drop-off is financial, and it occurs after the insurer has said yes. Even with approval in hand, only 54.5 percent of Medicare patients and 45.5 percent of commercially insured patients had a prescription that was both approved and filled within 90 days. The analysis found a steep, nearly linear relationship between out-of-pocket cost and the likelihood that a patient would actually fill the prescription. Among Medicare beneficiaries, fill rates were 84.9 percent when out-of-pocket costs were 15 dollars or less, and 76.7 percent when costs ranged from just over 15 dollars to 175 dollars. But when costs climbed into the 175-to-500-dollar range, fill rates collapsed to 38 percent, and they fell further to 29.2 percent when costs ranged from just over 500 dollars to 2,000 dollars.

Commercially insured patients showed the same pattern, with even steeper penalties at the high end. Fill rates were 80 percent when out-of-pocket costs were 15 dollars or less and 71.3 percent in the 15-to-175-dollar band, but only 30.9 percent when costs ranged from just over 500 to 2,000 dollars, and a mere 21.6 percent when costs exceeded 2,000 dollars. In other words, roughly four out of five patients facing modest copays filled their prescriptions, while fewer than one in four did so when confronted with four-figure cost-sharing. Because specialty oral anticancer drugs are typically covered under pharmacy benefits rather than medical benefits, patients encounter these cost-sharing requirements directly and often unexpectedly, sometimes at the very moment they are processing a frightening new diagnosis.

Senior author Jalpa A. Doshi, the Leon Hess Professor of Internal Medicine and a senior fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania, framed the findings as a map of where the prescription pathway fails. She noted that these blood cancer medications can be life-prolonging, but that insurance coverage requirements and high out-of-pocket costs can delay or limit access, and that the national benchmark her team constructed helps identify exactly where patients encounter barriers along the way. Doshi also emphasized that getting an insurer to approve a cancer drug is only the first hurdle, describing a second drop-off at the pharmacy counter when patients face high out-of-pocket costs. For Medicare beneficiaries, she pointed to the new annual out-of-pocket cost cap and the Medicare Prescription Payment Plan, which allows patients to spread prescription costs across the year, as potentially meaningful relief, though she stressed that awareness and enrollment will be critical if patients are to benefit.

The comparison between insurance types carries its own policy implications. Commercially insured patients fared worse on nearly every measure: higher initial rejection rates, lower final approval rates, and lower combined approval-and-fill rates. The authors suggest that reforms to prior authorization processes, drug coverage rules, and cost-sharing structures may be needed to ensure that a patient’s access to oral cancer drugs is not determined by the arbitrary design of the insurance plan they happen to hold. Such reforms could include standardizing and expediting prior authorization for oncology medications, requiring formularies to cover at least one drug within each therapeutic class, and capping specialty drug cost-sharing for commercially insured patients in ways that mirror the protections now phasing in for Medicare.

For a field that has celebrated the scientific triumph of targeted oral oncology, the study is a sobering reminder that a molecule’s efficacy is meaningless if it never reaches the bloodstream. The technical achievements are real: kinase inhibitors, immunomodulators, and proteasome inhibitors taken as daily pills have converted once-fatal diagnoses into manageable chronic conditions for many patients. But the delivery system wrapped around those molecules, with its prior authorization forms, formulary exclusions, and deductible-driven cost-sharing, is failing a substantial fraction of the very patients the drugs were designed to help. The Penn-led analysis turns that failure into measurable, comparable numbers, giving policymakers, insurers, and advocacy organizations a concrete benchmark against which future reforms, from streamlined authorization to expanded payment plans, can be judged. Whether the next generation of blood cancer patients will face the same gauntlet will depend on how quickly those reforms move from the pages of journals into the mechanics of insurance plans.

Subject of Research: Insurance coverage barriers and out-of-pocket costs affecting access to oral blood cancer medications

Article Title: Insurance barriers limit access to blood cancer drugs

Article References: Insurance barriers limit access to blood cancer drugs. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: blood cancer, oral anticancer drugs, prior authorization, insurance coverage, out-of-pocket costs, Medicare, prescription fill rates, leukemia, lymphoma, multiple myeloma, pharmacy benefits, health policy

The research, published in the journal Supportive Care in Cancer, enrolled 203 patient-caregiver dyads in which the patient had a hematologic malignancy. Each member of the pair independently completed the EuroQol 5-Dimensions 5-Levels questionnaire, known as the EQ-5D-5L, one of the most widely used instruments in health-outcomes research. The tool asks respondents to rate themselves on five dimensions of health: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression, each on a five-level severity scale. Responses can be summarized as a single utility score, a number between 0 and 1 that anchors full health at 1 and death at 0, making the measure useful both for bedside assessment and for health-economic calculations such as quality-adjusted life years.

The central question was straightforward: when a caregiver answers these questions on a patient’s behalf, does the answer resemble what the patient would have said? The answer, by the statistical standards of psychometrics, was largely yes. Caregiver proxy ratings of the EQ-5D-5L utility score correlated strongly with patient self-ratings, with a correlation coefficient of 0.679, a value conventionally interpreted as a strong positive association. At the level of individual dimensions, correlations ranged from 0.518 to 0.695, all statistically significant. Agreement, a stricter test than correlation because it penalizes systematic bias, was also solid: the intraclass correlation coefficient for utility scores was 0.730, with a 95 percent confidence interval of 0.658 to 0.788, a range that researchers typically classify as good reliability.

Dimension-by-dimension, the picture held up. Exact agreement between what caregivers reported and what patients reported about themselves ranged from 66.5 percent to 84.2 percent across the five EQ-5D-5L domains. In practical terms, when a caregiver marked a patient as having no problems walking, or severe pain, or difficulty with usual activities, that judgment matched the patient’s own answer roughly two-thirds to more than four-fifths of the time. For a population in which fatigue, cytopenias, and treatment toxicity often make self-report impossible, the researchers conclude that caregivers may serve as reliable proxies for assessing health-related quality of life in patients with hematologic malignancies.

Yet the study also uncovered a systematic wrinkle that clinicians should not ignore. Caregivers who were themselves struggling emotionally tended to paint a darker picture of their relative’s condition than the patients did. Greater anxiety symptoms among caregivers, measured with the seven-item Generalized Anxiety Disorder scale, were significantly associated with overestimation of the patients’ symptom burden, with a correlation coefficient of 0.408. Depressive symptoms, assessed with the nine-item Patient Health Questionnaire, showed a similar but weaker association, at 0.288. Both relationships were highly statistically significant. In other words, an anxious or depressed caregiver watching a loved one through chemotherapy may project some of that distress onto the patient’s own experience, rating symptoms as worse than the patient reports them to be.

This phenomenon, known in the literature as the proxy-rating bias, has been documented across cancer care and beyond. Previous systematic reviews of caregiver responses for patient quality-of-life assessment in adult oncology have found that proxies generally track patient self-reports reasonably well but tend to overestimate physical and emotional symptom burden. Studies in glioma patient-caregiver dyads have similarly shown that the psychosocial functioning of the rater influences rating accuracy, and research in dementia care has revealed substantial discrepancies between self- and proxy-rated quality of life. The new findings extend this evidence into hematologic malignancies, a population that has historically been underrepresented in quality-of-life research compared with solid tumors, partly because the episodic and often acute nature of blood cancers complicates longitudinal patient-reported outcome collection.

The methodological design of the study reflects careful attention to measurement quality. Beyond the EQ-5D-5L, caregivers completed the Family APGAR Index, a brief instrument capturing their perception of family functioning across adaptability, partnership, growth, affection, and resolve. The choice of the five-level version of the EQ-5D rather than the older three-level version matters as well: the five-level format reduces ceiling effects and improves discrimination among patients with mild to moderate impairment, which is essential when the goal is to detect subtle differences between raters. The Chinese EQ-5D-5L value set was used to compute utility scores, anchoring the analysis in a validated preference-based framework. Agreement statistics followed established conventions, with intraclass correlation coefficients interpreted according to widely accepted guidelines and categorical agreement benchmarked against classic standards for observer agreement research.

The clinical implications are twofold. First, the results legitimize a pragmatic workflow: when a patient with a hematologic malignancy cannot complete a quality-of-life assessment, whether because of severe illness, cognitive impairment, or the sheer exhaustion of intensive therapy, a well-informed caregiver’s report can stand in with acceptable fidelity. This matters for symptom monitoring, which randomized trials in oncology have shown can improve quality of life and even survival when patient-reported outcomes are systematically collected during routine treatment. It also matters for health-economic evaluation, where proxy utility scores are often needed to estimate the value of new therapies for blood cancers, a field in which cost-effectiveness analysis has grown rapidly. Second, the findings argue for screening caregivers themselves. Because caregiver anxiety and depression distort proxy ratings, treating the caregiver’s psychological distress is not only an act of compassion but also a way to sharpen the accuracy of the clinical data the care team depends on.

The study was approved by the Xiangya Hospital Ethics Committee with written informed consent obtained in accordance with the Declaration of Helsinki, and the authors report no competing interests. The work was supported by the Hunan Provincial Natural Science Foundation of China and the China Postdoctoral Science Foundation. The research team, led by corresponding author Yajing Xu with first author Wei Qin, notes that data are available from the lead and corresponding authors upon reasonable request. As blood cancers continue to impose a rising global burden, with incidence and disability from hematologic malignancies climbing over the past three decades, the message of this study is quietly empowering: the people who know patients best, and who sit beside them through the hardest days, can be trusted to give voice to what those patients are too sick to say, provided clinicians remember to ask how the storytellers themselves are doing.

Subject of Research: Caregiver proxy assessment of health-related quality of life in patients with hematologic malignancies

Article Title: Caregivers’ proxy assessments of health-related quality of life in patients with hematologic malignancies

Article References: Qin, W., Tong, F., Zeng, C., Qian, Z., & Xu, Y. (2026). Caregivers’ proxy assessments of health-related quality of life in patients with hematologic malignancies. Supportive Care in Cancer, 34(10), Article 964. https://doi.org/10.1007/s00520-026-11206-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11206-8

Keywords: hematologic malignancies, caregivers, proxy assessment, health-related quality of life, EQ-5D-5L, blood cancer, patient-reported outcomes, anxiety, depression, family functioning, symptom burden, supportive care